Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Despite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular entities were approved during the month and several other drugs also received the nod.Meanwhile, Blueprint Medicines Corp (NASDAQ: BPMC) faced disappointment at the FDA altar, as its NDA for avapritinib for treating fourth-line gastrointestinal stromal tumor was clamped with a complete response letter.Here are the key PDUFA dates scheduled for the unfolding month.Merck's Antibiotic Combo Up Before FDA For Label Expansion * Company: Merck & Co., Inc. (NYSE: MRK) * Type of Application: sNDA * Candidate: Recarbrio * Indication: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia * Date: June 4Recarbrio is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Viela Eyes Commercial...

Changes Are Coming For Airline ETF, Slight Reduction In Dependence on Top 4 US Carriers

The U.S. Global Jets ETF (NYSE: JETS), the lone exchange-traded fund dedicated to airline equities, is set to undergo some changes that will slightly reduce the fund's exposure to the four largest domestic carriers.What To KnowJETS follows the U.S. Global Jets Index, which typically includes 30 to 35 stocks. When that index rebalances in March, June, September and December, it assigns weights of 12% to the four largest U.S. carriers.Currently, Southwest (NYSE: LUV), American Airlines (NASDAQ: AAL), Delta Air Lines (NYSE: DAL) and United Airlines (NASDAQ: UAL) combine for about 42% of the fund's weight.JETS' next largest component doesn't command even 5% of the fund's weight, but the fund could be poised to become more diverse.Why It's ImportantIn a recent filing with the Securities and Exchange Commission, U.S. Global notes the JETS index could include 39 companies going forward, potentially increasing its exposure to Canadian carriers while possibly lowering weights to...

Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'

Drugmaker Eli Lilly And Co (NYSE: LLY) started a human study of a potential antibody treatment for COVID-19 patients, and CEO David Ricks said on Fox Business that it is the first of its kind.Lilly's Brand New Medicine Eli Lilly's medicine to treat COVID-19 patients is the first of its kind, as it consists of antibodies found in a recovered patient's cells. In contrast, other drugs and therapies are merely "repurposed" from other uses, Ricks said.Eli Lilly scientists collaborated with Canada-based AbCellera to engineer a treatment out of the "very best one or two" antibodies it can find out of millions of cells, the CEO said. The initial study will consist of less than 40 patients, and results are expected in a "couple of weeks," he said. Lilly's Production Timeline Eli Lilly has already started the process of ramping up production for its hopeful therapy despite it being in the early...

Coronavirus latest: Monday, June 1

As protests over the George Floyd case continue to grow, worries over the spread of coronavirus weigh heavily on medical experts as Gilead Sciences and Eli Lilly announce news about their vaccine trials. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus....

Citi Option Trader Bets Nearly $1M On Long-Term Upside

Shares of Citigroup Inc (NYSE: C) traded higher Monday as traders became increasingly optimistic that a combination of Federal Reserve stimulus and a potential coronavirus vaccine can help big banks weather the economic downturn.Despite concerns over the impact of emergency interest rate cuts and loan losses, Citigroup shares were rocketing higher in the past week. Several options traders made large bets on Monday that the stock is just getting started.The Citigroup Trades On Monday morning, Benzinga Pro subscribers received eight option alerts related to unusually large Citigroup option trades. Here are a handful of the largest: * At 10:09 a.m. ET, a trader bought 500 Citigroup call options with a $50 strike price expiring on Jun. 12. The contracts were purchased near the ask price at $1.601 and represented an $80,050 bullish bet. * At 11:43 a.m. ET, a trader sold 2,026 Citigroup call options with a $52 strike price expiring...